As Novartis moves toward shedding generics subsidiary Sandoz, which it touts as a global leader in off-patent generic and biosimilar drugs, Sandoz has agreed a multi-year strategic partnership with Just –Evotec Biologics, the Seattle, Washington-based US subsidiary of Germany’s Evotec, to develop and manufacture biosimilars.
German CDMO Evotec is to acquire compatriot company Central Glass Germany from Japanese owner Central Glass for a nominal price of €1. The transaction, which remains subject to the usual closing conditions, is expected to complete on Nov. 1.
German biopharma Boehringer Ingelheim, compatriot CDMO Evotec and French diagnostics firm BioMérieux have formed a joint venture to develop a new approach to fight the rise of antibiotic-resistant infections.
German drug discovery and development company Evotec and Canadian therapeutics company Sernova are collaborating to develop a diabetes treatment based on induced pluripotent stem cells (iPSC). As part of the agreement, Evotec will make an equity investment in Sernova of €20 million.
German drug discovery and development company Evotec has entered into two separate collaborations with major pharma firms during January.
US drugmaker Bristol Myers Squibb has chosen Leiden in the Netherlands for a new cell therapy manufacturing site in Europe as it continues to expand and develop treatments for patients with aggressive hematological cancers.
German drug discovery and development group Evotec has started building a biologics manufacturing facility at its Campus Curie site in Toulouse, France.
German drug discovery and development company Evotec has struck four separate partnership agreements during August.
Evotec has formed a strategic partnership with Leon-Nanodrugs, a German-based provider of nanotechnology for the pharmaceutical industry.
